Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 1;130(17):2897-2903.
doi: 10.1002/cncr.35357. Epub 2024 May 8.

Top advances of the year: Perioperative therapy for lung cancer

Jacqueline V Aredo  1 , Heather A Wakelee  2
Affiliations
Free article

Top advances of the year: Perioperative therapy for lung cancer

Jacqueline V Aredo et al. Cancer. .
Free article

Abstract

Emerging data supporting the rise of perioperative immune checkpoint inhibitors (ICIs) as a standard of care in the treatment of early stage, surgically resectable non-small cell lung cancer (NSCLC) dominated the NSCLC news in 2023. Adjuvant pembrolizumab became the second adjuvant ICI to receive US Food and Drug Administration approval in early 2023 after the 2021 approval of adjuvant atezolizumab and the 2022 approval of neoadjuvant nivolumab with chemotherapy. Subsequently in 2023, multiple phase 3 trials examining perioperative ICIs were positive and demonstrated clinically meaningful outcomes by prolonging event-free survival, improving pathologic complete response rates, and trending toward improved overall survival in most. Perioperative pembrolizumab became the first ICI to attain US Food and Drug Administration approval in this setting through the KEYNOTE-671 trial (ClinicalTrials.gov identifier NCT03425643), which also demonstrated a definitive overall survival benefit in the entire study population. However, questions remain regarding patient selection for either approach and how we can optimize biomarkers to determine who needs adjuvant therapy after surgery.

Keywords: adjuvant; lung cancer; neoadjuvant; perioperative immunotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17‐48. doi:10.3322/caac.21763
    1. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973‐1985. doi:10.1056/nejmoa2202170
    1. US Food and Drug Administration (FDA). FDA approves neoadjuvant nivolumab and platinum‐doublet chemotherapy for early‐stage non‐small cell lung cancer. FDA; 2023. Accessed December 20, 2022. https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐appro...
    1. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non‐small‐cell lung cancer (IMpower010): a randomised, multicentre, open‐label, phase 3 trial. Lancet. 2021;398(10308):1344‐1357. doi:10.1016/s0140‐6736(21)02098‐5
    1. US Food and Drug Administration (FDA). FDA approves atezolizumab as adjuvant treatment for non‐small cell lung cancer. FDA; 2023. Accessed December 20, 2023. https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐appro...

MeSH terms

Associated data